Envoy Medical Reports Q3 2026 Results, Highlights Trial Progress
Envoy Medical, Inc. announces Q3 2026 financial results, showcasing progress in its pivotal cochlear implant trial and expanding its patent portfolio.
Vistance Networks announces Q3 results, $100M buyback plan
Vistance Networks reveals strong Q3 results and a new $100M stock repurchase program, signaling confidence in its financial future.
LCI Industries reports Q3 results, highlights merger plans
LCI Industries announces third-quarter results with a focus on growth in adjacent markets and plans for a merger with Patrick Industries.
Tecnoglass Holdings reports third-quarter results for 2026
Tecnoglass Holdings Inc. announces its third-quarter 2026 financial results, revealing key insights into its performance and the flat glass industry.
Open Text announces Q1 results and dividend declaration
Open Text Corp reports Q1 2026 financial results and declares a $0.28 dividend per share, reinforcing its commitment to shareholder returns.
Evolent Health reports strong Q3 2026 results, revenue growth
Evolent Health, Inc. announces Q3 2026 financial results, showcasing revenue growth and a focus on oncology services amid increasing demand from health plan customers.
ConocoPhillips Reports Strong Q3 Results, Increases Dividend
ConocoPhillips announces robust Q3 earnings and an 11% dividend increase, reflecting strong operational performance and cash flow.
Kimbell Royalty Partners Reports Record Q3 Results, Redeems Units
Kimbell Royalty Partners, LP announces record Q3 2026 results with strong production and revenue growth, alongside plans to redeem preferred units.
Appian Corp posts strong Q3 results, boosts cloud revenue 20%
Appian Corp announces a 20% increase in cloud subscriptions revenue in Q3 2026, reflecting strong growth in the prepackaged software sector.
Xeris Biopharma Reports Strong Q3 Results, Raises Revenue Outlook
Xeris Biopharma Holdings, Inc. announces a 44% revenue increase in Q3 2026 and raises its full-year guidance, signaling strong growth in the pharmaceutical sector.
Akebia Therapeutics Reports Q3 2026 Results, Highlights Growth
Akebia Therapeutics announces Q3 2026 financial results, showcasing growth in Vafseo usage and plans to enhance its position in kidney disease treatment.
McGraw Hill Reports Fiscal First-Quarter Results, Revenue Declines
McGraw Hill, Inc. announces fiscal first-quarter results with a 5.5% revenue decline, focusing on digital growth and AI integration in education.
Orion Energy Systems announces quarterly financial results
Orion Energy Systems, Inc. releases quarterly financial results for Q3 2026, impacting its performance in the electric lighting and wiring equipment sector.
Evergy reports third-quarter results for 2026
Evergy, Inc. announces third-quarter results, reflecting its financial condition and operational performance as of September 30, 2026.
WW International Reports Q3 2026 Results with Profit Growth
WW International, Inc. announces Q3 2026 results, showing increased revenue and a return to profitability, signaling growth in the personal services industry.
Astec Industries Reports Q3 Results Amid Economic Challenges
Astec Industries Inc. reports third-quarter results with slight sales increase but net loss, adjusting financial outlook amid economic uncertainty.
Teleflex reports Q3 results, raises EPS guidance for 2026
Teleflex Inc. announces third-quarter financial results, reporting revenue growth and increased earnings per share, raising its guidance for the full year.
N-able Reports Strong Q3 Results, Boosts ARR by 5%
N-able, Inc. announces a 5% growth in annual recurring revenue in Q3 2026, reflecting strong market demand for its cybersecurity solutions.
Keel Infrastructure Reports Third Quarter 2026 Results
Keel Infrastructure Corp. announces financial results for Q3 2026, highlighting progress in construction and strong liquidity.
Avalo Therapeutics Reports Q3 2026 Results and Pipeline Updates
Avalo Therapeutics announces Q3 2026 financial results, focusing on drug development and financial health, with plans for Phase 3 trials in 2027.